(190) found that, although the number of TIGIT+ve NK cells in AML patients were significantly lower in comparison to the healthy controls, these TIGIT+ve NK cells also express high levels of ARs CD16 and CD160. This evidence concerns the gene TIGIT and acute myeloid leukemia.